NASDAQ:JBIO

Jade Biosciences (JBIO) Stock Price, News & Analysis

Jade Biosciences logo
$15.31 +0.25 (+1.66%)
Closing price 04:00 PM Eastern
Extended Trading
$15.32 +0.00 (+0.03%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Jade Biosciences Stock (NASDAQ:JBIO)

Advanced

Key Stats

Today's Range
$15.00
▼
$15.54
50-Day Range
$13.41
▼
$18.18
52-Week Range
$11.02
▼
$28.00
Volume
1.02 million shs
Average Volume
825,484 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.00
Consensus Rating
Moderate Buy

Company Overview

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease.

The company’s lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys.

Jade’s pipeline is focused on potential therapies for autoimmune conditions. The company’s work is at the drug-development stage, and its programs are intended to address diseases with significant unmet treatment needs.

AI Generated. May Contain Errors.

Jade Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

JBIO MarketRank™: 
2.25569585506 of 5 stars

Jade Biosciences scored higher than 45% of companies evaluated by MarketBeat, and ranked 545th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Jade Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Jade Biosciences has a consensus price target of $51.00, representing about 233.1% upside from its current price of $15.31.

  • Amount of Analyst Coverage

    Jade Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Jade Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Jade Biosciences are expected to decrease in the coming year, from ($2.51) to ($2.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Jade Biosciences is -8.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Jade Biosciences is -8.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Jade Biosciences has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    21.20% of the float of Jade Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Jade Biosciences has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Jade Biosciences has recently decreased by 7.46%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Jade Biosciences does not currently pay a dividend.

  • Dividend Growth

    Jade Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Jade Biosciences has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for Jade Biosciences this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Jade Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.06% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Jade Biosciences has minimal institutional ownership at this time.

  • Read more about Jade Biosciences' insider trading history.
Receive JBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JBIO Stock News Headlines

Equities Analysts Issue Forecasts for JBIO FY2026 Earnings
ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
Jade Biosciences (JBIO) Stock Price Target 2026
Jade Biosciences (NASDAQ:JBIO) Upgraded at Wall Street Zen
See More Headlines

JBIO Stock Analysis - Frequently Asked Questions

Jade Biosciences' stock was trading at $15.43 at the beginning of the year. Since then, JBIO stock has decreased by 0.8% and is now trading at $15.31.

Jade Biosciences, Inc. (NASDAQ:JBIO) released its earnings results on Friday, November, 13th. The company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.73) by $0.31.

Top institutional investors of Jade Biosciences include Bellevue Group AG (6.75%), State Street Corp (4.09%), RA Capital Management L.P. (2.89%) and Pictet Asset Management Holding SA (1.90%).

Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/13/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:JBIO
Previous Symbol
NASDAQ:JBIO
CIK
1798749
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

High Price Target
$77.00
Low Price Target
$40.00
Potential Upside/Downside
+233.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.41 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-42.80%
Return on Assets
-40.09%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.03
Quick Ratio
14.93

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.58 per share
Price / Book
2.33

Miscellaneous

Outstanding Shares
69,190,000
Free Float
53,234,000
Market Cap
$1.06 billion
Optionable
Optionable
Beta
1.81
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

This page (NASDAQ:JBIO) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners